4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000950170-24-030189
Chief Executive Officer sold 14,385 shares at an average $77.04 ($1,108,263)
- Chief Executive Officer acquired 28,250 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2024-03-10 | Option exercise | +19,250 | 213,507 | D | ||
| Kulkarni Samarth Chief Executive Officer | 2024-03-11 | Sale | −9,802 | $78.26 | $767,105 | 203,705 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-03-11 | Option exercise | +9,000 | 212,705 | D | ||
| Kulkarni Samarth Chief Executive Officer | 2024-03-12 | Sale | −4,583 | $74.44 | $341,159 | 208,122 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2024-03-10 | Option exercise · Restricted Stock Units | −19,250 | 57,750 | D | ||
| Kulkarni Samarth Chief Executive Officer | 2024-03-11 | Option exercise · Restricted Stock Units | −9,000 | 9,000 | D | ||
| Open-market sales · 14,385 sh · avg $77.04 · $1,108,263 | |||||||
Loading xslF345X05/ownership.xml…